07.01.2022 - 08:03:46

SYNLAB acquires Sistemas Gen?micos of the Ascires Group in Spain, further strengthening its European leadership in genetics

in 2021, Sistemas Gen?micos is a key player in the Spanish diagnostics market. The laboratory has a strong track record in genetic sequencing as well as in molecular biology and genetics, with more than 20 years of experience and over 100 highly-qualified experts. More than that, the laboratory's substantial expertise in bioinformatics - the software-supported analysis of biological data - makes it a frontrunner in the digital transformation of diagnostics.

Mathieu Floreani, CEO of the SYNLAB Group, underlines the strategic value of this acquisition: "Looking at the diagnostics market, genetic testing and counselling as well as the digitization and automation of diagnostic services bear vast growth potentials in the future. Sistemas Gen?micos is the only laboratory on an international level that is certified to provide genetic analysis and diagnosis services during the entire human life cycle, and they are a leader in bioinformatics. Hence, they will perfectly enhance and complement the SYNLAB network. We are looking forward to welcoming our new colleagues, exchanging knowledge, and continuing our growth path together."

CEO of Ascires Grupo Biom?dico, Lorena Saus, highlights Ascires' strategic rationale to focus on integrated precision medicine in both clinical and healthcare activities: "Ascires continues to focus on integrating genomic data with clinical information from diagnostic imaging and nuclear medicine, a core activity of the group for over 50 years. Thanks to extraordinary precision acquired through our longstanding expertise, Ascires has become a benchmark organisation in medical specialties such as neurology and cardiology. There is no doubt that Sistemas Gen?micos' integration into the SYNLAB network will be a catalyst for both companies and their excellent professionals".

The acquisition of Sistemas Gen?micos is part of SYNLAB's ambitious M&A strategy. The company continues to pursue acquisitions focused on generating synergies, extending its network of laboratories and increasing its technological capacity, allowing it to complement its services as well as its patient and customer base. SYNLAB expects to spend more than ?200 million on M&A in 2022.

For more information:

Media contact: Diana Tabor, FTI Consulting +49 (0) 151 Investor contact: Mark Reinhard, SYNLAB +49 (0) 170 118


- SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medical diagnostic services company and offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.

- Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.

- SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. More than 20,000 employees, including over 1,200 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB carries out ~500 million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020.

- More information can be found on [1] Including SARS-CoV-2 Diagnosis

07.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at

Language: English Company: SYNLAB AG Moosacher Stra?e 88 80809 Munich

Germany Phone: +49 1701183753 E-mail: Internet: ISIN: DE000A2TSL71 WKN: A2TSL7 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1265838 ? End of News DGAP News Service